Adjuvant Ipilimumab in High-Risk Uveal Melanoma

• Published in: Cancers 2019-01, Vol.11 (2), p.152
• Main Authors: Fountain, Eric, Bassett, Roland L, Cain, Suzanne, Posada, Liberty, Gombos, Dan S, Hwu, Patrick, Bedikian, Agop, Patel, Sapna P
• Format: Article
• Language: English
• Subjects: Clinical trials; Consent; CTLA-4 protein; Dosage; Enrollments; Gene expression; Hepatitis; Immune checkpoint; Immunotherapy; Melanoma; Metastases; Metastasis; Patients; PD-1 protein; Radiation therapy; Toxicity
• ISSN: 2072-6694; 2072-6694
• DOI: 10.3390/cancers11020152

Uveal melanoma is a common intraocular malignant tumor that is uniformly fatal once metastatic. No effective adjuvant therapy currently exists to reduce the risk of distant metastasis after definitive treatment of the primary lesion. Immunotherapy has been used effectively in the adjuvant setting in locally advanced cutaneous melanoma. We performed a Phase I/II clinical trial of adjuvant ipilimumab in high-risk primary uveal melanoma with distant metastasis-free survival (DMFS) as the primary objective. A total of 10 patients with genomically high-risk disease were treated: three at a dose of 3 mg/kg and seven at 10 mg/kg. Two of the seven patients at the higher dose had to discontinue therapy secondary to grade 3 toxicity. At 36 months follow-up, 80% of patients had no evidence of distant disease (95% CI, 58.7⁻100). With recent advancements in CTLA-4 inhibition, PD-1 inhibition, and combined checkpoint blockade, immunotherapy is a promising avenue of treatment in uveal melanoma. Further clinical trials are needed to elucidate the role of immunotherapy in the adjuvant setting.